Pictet Asset Management Holding SA trimmed its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 22.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 588,009 shares of the biopharmaceutical company’s stock after selling 165,686 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.60% of Ultragenyx Pharmaceutical worth $9,004,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of RARE. Assenagon Asset Management S.A. increased its holdings in shares of Ultragenyx Pharmaceutical by 295.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 477,869 shares of the biopharmaceutical company’s stock worth $7,182,000 after acquiring an additional 357,005 shares during the period. BlackRock Inc. bought a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $355,746,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $6,397,000. Deutsche Bank AG acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $5,503,000. Finally, Corient Private Wealth LP acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $4,644,000. Institutional investors and hedge funds own 97.67% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. HC Wainwright dropped their price target on shares of Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, September 3rd. UBS Group started coverage on Ultragenyx Pharmaceutical in a research report on Thursday, October 15th. They set a “neutral” rating and a $16.00 price objective for the company. Morgan Stanley boosted their price objective on Ultragenyx Pharmaceutical from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 4th. Evercore lowered Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price objective for the company. in a report on Thursday, September 3rd. Finally, Citigroup lowered their target price on Ultragenyx Pharmaceutical from $32.00 to $22.00 and set a “buy” rating on the stock in a research report on Thursday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $29.79.
Ultragenyx Pharmaceutical Price Performance
RARE stock opened at $16.08 on Monday. The company has a 50-day simple moving average of $15.29 and a 200 day simple moving average of $22.52. The company has a market capitalization of $1.64 billion, a P/E ratio of -3.10 and a beta of 0.37. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $12.73 and a fifty-two week high of $39.89.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The business had revenue of $173.00 million for the quarter, compared to analysts’ expectations of $182.49 million. During the same quarter last year, the firm posted ($1.81) earnings per share. The company’s revenue for the quarter was up 8.2% compared to the same quarter last year. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.21 EPS for the current year.
Insider Activity
In other news, CFO Howard Horn sold 7,066 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the completion of the transaction, the chief financial officer directly owned 89,229 shares in the company, valued at $1,362,526.83. This trade represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 8,510 shares of company stock valued at $127,561 in the last ninety days. Company insiders own 5.20% of the company’s stock.
Ultragenyx Pharmaceutical Profile
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.
See Also
- Five stocks we like better than Ultragenyx Pharmaceutical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
